Zepbound vs Mounjaro vs Wegovy vs Ozempic: Four Brands, Two Medications

Zepbound, Mounjaro, Wegovy, Ozempic. Patients bring these four names into discovery calls every week, usually after a friend, a commercial, or a TikTok convinced them one of the four is the one that really works. The part that rarely gets explained up front: those four brands are only two medications. Wegovy and Ozempic are both semaglutide. Zepbound and Mounjaro are both tirzepatide. Four names for two drugs is a labeling and marketing story, not a medical one.

This guide sorts out which brand is which, what each one is FDA-approved to treat, what the head-to-head trial actually found, and why the provider managing your treatment matters more than the name printed on the pen.

Four Brand Names, Two Medications

Semaglutide is made by Novo Nordisk and sold as Ozempic, Wegovy, and Rybelsus (an oral tablet). Tirzepatide is made by Eli Lilly and sold as Mounjaro and Zepbound. Within each pair, the molecule in the injection is identical. What changes is the FDA indication, meaning what the label says the drug is approved to treat.

Brand	Active medication	FDA-approved for	Maker
Ozempic	Semaglutide	Type 2 diabetes	Novo Nordisk
Wegovy	Semaglutide	Chronic weight management	Novo Nordisk
Mounjaro	Tirzepatide	Type 2 diabetes	Eli Lilly
Zepbound	Tirzepatide	Chronic weight management	Eli Lilly

So when someone asks whether Zepbound beats Ozempic, they're really asking two questions at once: how tirzepatide compares to semaglutide, and how a weight loss label differs from a diabetes label. Worth taking those one at a time.

Ozempic vs Wegovy: Same Molecule, Different Label

Both are weekly semaglutide injections. Ozempic carries the type 2 diabetes approval. Wegovy carries the chronic weight management approval, and it exists because semaglutide proved effective enough for weight loss that Novo Nordisk ran dedicated weight loss trials (the STEP program) and earned a separate approval with a dosing schedule built for that purpose. In those trials, patients on semaglutide 2.4 mg lost about 15 percent of their body weight over 68 weeks.

Why do so many people without diabetes end up on Ozempic anyway? Insurance, mostly. Many plans handle diabetes coverage and weight loss coverage under completely different rules, so the brand a patient lands on often reflects their benefits paperwork rather than their biology.

There's also a newer branch on the semaglutide family tree. An oral Wegovy pill (25 mg semaglutide) was FDA-approved in December 2025 and launched at $149 per month without insurance, with trial participants losing roughly 17 percent of body weight compared to 2.7 percent on placebo. If needles are what's been holding you back, our GLP-1 pills vs injections guide walks through the trade-offs.

Mounjaro vs Zepbound: Same Molecule, Different Label

Both are weekly tirzepatide injections. Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management. Tirzepatide is a synthetic peptide that activates two receptors, GLP-1 and GIP, instead of the single GLP-1 target semaglutide works on. That dual mechanism is the reason it gets billed as the stronger option for weight loss. We cover the peptide side of the story in plain language in our is tirzepatide a peptide explainer.

Dosing for both tirzepatide brands starts at 2.5 mg and steps up gradually to a maximum of 15 mg weekly. Our tirzepatide dosage chart covers what to expect at each level and when providers adjust the schedule. In the SURMOUNT weight loss trials, tirzepatide at 15 mg produced 22.5 percent average body weight loss over 72 weeks.

Zepbound vs Wegovy: What the Head-to-Head Trial Found

For years, comparing these medications meant comparing separate trials with different designs. Then came SURMOUNT-5, a randomized trial that tested tirzepatide against semaglutide directly in adults with obesity or overweight and no diabetes.

At 72 weeks, the tirzepatide group averaged 20.2 percent body weight loss. The semaglutide group averaged 13.7 percent. Waist circumference dropped 18.4 centimeters with tirzepatide versus 13.0 with semaglutide, and tirzepatide patients were more likely to reach the 10, 15, 20, and 25 percent weight loss milestones. Side effects looked similar in both groups: mostly stomach-related, mostly mild to moderate, mostly during dose increases.

That looks like a clean win for tirzepatide. The heart data complicates it.

A real-world study from Mass General Brigham (the STEER study) followed patients who already had cardiovascular disease and found semaglutide associated with a 57 percent greater reduction in major cardiac events than tirzepatide. The study was observational and short, and no head-to-head randomized trial on heart outcomes had been completed as of mid-2026, so nobody can honestly declare a winner there. Separate cohort data presented at Heart Rhythm 2026 tied GLP-1 use to lower atrial fibrillation risk in more than 13,000 patients, independent of how much weight they lost. The takeaway from all of it: these are metabolic medications with effects on your heart, blood sugar, and appetite signaling at the same time, which is why the biggest number on the scale is not the only number that matters, especially if heart health is part of your picture.

Collin Dees, MPAS, PA-C, a physician assistant on our weight loss team, makes this point with patients constantly: a trial average is a starting assumption, not a prediction about you. Some people lose more on semaglutide than the tirzepatide average. Some plateau on tirzepatide. The full compound-level comparison, including mechanisms, side effects, and who tends to respond to which, lives in our semaglutide vs tirzepatide breakdown.

What the Four Brands Cost

Without insurance, brand-name Wegovy runs roughly $1,300 to $1,600 per month and Zepbound roughly $1,000 to $1,200. The oral Wegovy pill launched at $149 per month. Insurance changes everything, and the rules differ between diabetes and weight loss indications, which is a big part of why patients get steered toward one brand over another. Medicare's new GLP-1 Bridge program began taking prior authorizations on July 1, 2026, giving eligible Part D members certain GLP-1 medications at a flat $50 monthly copay. For brand, compounded, and insurance numbers in one place, our tirzepatide cost guide has the full breakdown.

Brand-Name vs Compounded: The Other Comparison That Matters

While patients compare the four brands against each other, the FDA has spent 2026 drawing a much harder line between all of them and their compounded copies.

The agency has proposed permanently barring large-scale compounding facilities from producing semaglutide, tirzepatide, and liraglutide, with the public comment window running through July 30, 2026. It has also sent three waves of warning letters to telehealth companies over compounded GLP-1 marketing: roughly 80 letters in September 2025, 30 in March 2026, and 25 more in June 2026, many citing claims that a compounded product is the "same" as the FDA-approved drug. The safety reports explain the concern. The FDA has logged more than 455 adverse event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide, many involving dosing errors from patients drawing their own doses out of multidose vials.

So before you weigh Zepbound against Wegovy, confirm that what you're being offered is actually either one. A legitimate medical weight loss program can tell you exactly which medication you're getting, who made it, and what your labs showed before it was prescribed. That's the standard our semaglutide weight loss program in South Portland is built on.

Why Provider Fit Beats Brand Choice

The brand question assumes the medication is the whole treatment. It isn't even close.

Start with labs. Fasting insulin and A1C reveal insulin resistance, which shifts the math toward tirzepatide's dual-receptor mechanism for some patients. A full thyroid panel matters because an undertreated thyroid will stall weight loss no matter which pen you inject. Sex hormones, cortisol, and inflammatory markers shape appetite, fat storage, and energy in ways a prescription alone never touches. This is what an 80+ biomarker panel is for. It shows your provider which medication fits your metabolic picture, and whether medication is even the right first move.

Then there's muscle. A Stanford study published in PNAS in June 2026 found that up to 21 percent of the weight lost on GLP-1 medication alone can be lean muscle. Pairing the medication with structured resistance training and adequate protein cut that to 7 percent. No brand solves this on its own. Tracking body composition instead of scale weight is the only way to catch it early, which is why every weight loss patient in our clinic gets an InBody 770 scan at baseline and throughout treatment. If holding onto strength while you lose is a worry, our muscle loss page goes deeper.

Plateaus happen on every brand too. Sometimes the fix is a dose change. Sometimes it's switching molecules, which we map out in our semaglutide-to-tirzepatide switching guide. And sometimes the stall traces back to a root cause no GLP-1 was ever going to fix, which is where a broader weight loss treatment plan earns its keep.

How Med Matrix Handles the Brand Question

Nobody picks a brand on the first phone call here. The process starts with a free discovery call, where a patient coordinator listens to your goals and symptoms, explains your options, and matches you with the right provider.

Testing comes next: a panel of 80+ lab markers, a full body composition scan, and in-depth health questionnaires. The medical team reviews all of it together, cross-referencing your symptoms with your biomarker patterns, before anyone writes anything. Then you get a full hour with your provider to go over every result and build the plan. If a GLP-1 medication fits, the choice between semaglutide and tirzepatide comes out of that data: your insulin markers, your thyroid, your hormones, your heart history, your goals. If something else is driving the weight, the plan says so instead.

From there it's ongoing support. Follow-up labs, dose adjustments as your body responds, body composition rechecks, and direct access to the care team. That structure has served 3,000+ patients across 7 providers, with a 4.9-star rating from 150+ Google reviews, and it's the same functional medicine approach we apply to everything: test first, treat what the data shows.

Frequently Asked Questions

Are Ozempic and Wegovy the same drug?

They contain the same drug, semaglutide, made by the same company. Ozempic is FDA-approved for type 2 diabetes, while Wegovy is approved for chronic weight management with a dosing schedule designed for weight loss. The molecule is identical; the label, dosing, and insurance handling differ.

Are Mounjaro and Zepbound the same drug?

Yes, both are tirzepatide from Eli Lilly. Mounjaro carries the type 2 diabetes approval and Zepbound carries the chronic weight management approval. Which one a provider prescribes depends on your diagnosis and your coverage.

Which brand produces the most weight loss?

In the SURMOUNT-5 head-to-head trial, tirzepatide (the medication in Zepbound and Mounjaro) averaged 20.2 percent body weight loss over 72 weeks versus 13.7 percent for semaglutide (the medication in Wegovy and Ozempic). Individual results vary widely, and factors like insulin resistance, thyroid function, and hormone balance influence which medication actually works better for a specific person.

Can I switch from Wegovy to Zepbound?

Yes. Patients switch because of plateaus, persistent side effects, updated lab results, or coverage changes. The switch isn't a straight swap, since tirzepatide restarts at its lowest dose and titrates up from there. A provider should manage the transition and monitor your labs along the way.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded versions are not FDA-approved, and the FDA has sent multiple waves of warning letters to companies claiming otherwise. The agency has logged more than 455 adverse event reports tied to compounded semaglutide, many from dosing errors, and has proposed permanently barring large-scale compounding of semaglutide and tirzepatide, with public comments open through July 30, 2026.

Do I need to pick a brand before my first visit?

No. The better order is labs first, medication second. An 80+ biomarker panel and a full hour with a provider will tell you which medication fits your body, or whether a different approach entirely will get you further.

Stop comparing brand names and find out what your labs say first. Get Your Free Guide + $100 Voucher and talk with a patient coordinator about whether medical weight loss is the right starting point for you.